Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Head Neck ; 44(6): 1442-1452, 2022 06.
Article in English | MEDLINE | ID: mdl-35355358

ABSTRACT

BACKGROUND: Associations between patient-reported outcomes and dose to organs at risk (OARs) may promote management and guide future investigations. METHODS: We retrospectively evaluated PROs and OAR dose in head and neck (H&N) cancer. RESULTS: In 169 patients, we identified weak associations between: "Difficulty swallowing/chewing" and increased mean RT dose to the oral cavity, larynx, pharyngeal constrictor muscles (PCM) and contralateral parotid; "choking/coughing" and larynx mean dose; "problems with mucus in mouth and throat" and oral cavity, contralateral parotid mean dose and parotid V30, contralateral submandibular gland and PCM mean dose; "difficulty with voice/speech" and oral cavity, contralateral parotid, contralateral submandibular gland and larynx mean dose; and "dry mouth" and ipsilateral submandibular gland, oral cavity and PCM mean dose. CONCLUSION: We identified weak associations between PRO and dose to OARs-these data can guide on treatment management, patient counseling, and serve as a baseline for future investigations.


Subject(s)
Head and Neck Neoplasms , Radiotherapy, Intensity-Modulated , Head and Neck Neoplasms/radiotherapy , Humans , Organs at Risk , Parotid Gland , Patient Reported Outcome Measures , Radiation Dosage , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Retrospective Studies
2.
Head Neck ; 42(12): 3670-3677, 2020 12.
Article in English | MEDLINE | ID: mdl-32815253

ABSTRACT

BACKGROUND: Patient Reported Outcome (PRO) data comparing bolus (B-CP) with weekly (W-CP) cisplatin concurrent with radiation are lacking. METHODS: We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B-CP and 73% treated with W-CP. RESULTS: W-CP patients had a higher Charlson comorbidity index (CCI) (P = .004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self-reported dysphagia score were more often PEG dependent at the end of radiation therapy (P = .03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score (P = .06). The maximum decline in white cell count and absolute neutrophil count were greater in the W-CP group (P = .04, P = .01). CONCLUSION: Both B-CP and W-CP are well tolerated. PROs do not suggest a benefit to W-CP.


Subject(s)
Antineoplastic Agents , Head and Neck Neoplasms , Antineoplastic Agents/therapeutic use , Chemoradiotherapy/adverse effects , Cisplatin , Head and Neck Neoplasms/drug therapy , Humans , Patient Reported Outcome Measures , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...